Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadopiclenol for Detection of Early Leptomeningeal Disease
NCT07415018Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gadopiclenol in leptomeningeal disease (LMD), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
gadopiclenol
03
Conditions
leptomeningeal disease (LMD)
Beyond the preview
Go deeper on NCT07415018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07415018.